Anixa Biosciences, Inc. (ANIX)
3.35
-0.13
(-3.74%)
USD |
NASDAQ |
Aug 31, 16:00
3.365
+0.02
(+0.45%)
After-Hours: 20:00
Anixa Biosciences Cash from Operations (TTM) : -7.117M for April 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| April 30, 2026 | -7.117M |
| January 31, 2026 | -6.879M |
| October 31, 2025 | -7.173M |
| July 31, 2025 | -6.845M |
| April 30, 2025 | -7.977M |
| January 31, 2025 | -7.93M |
| October 31, 2024 | -7.335M |
| July 31, 2024 | -8.377M |
| April 30, 2024 | -7.179M |
| January 31, 2024 | -6.53M |
| October 31, 2023 | -6.209M |
| July 31, 2023 | -5.833M |
| April 30, 2023 | -5.784M |
| January 31, 2023 | -7.283M |
| October 31, 2022 | -6.492M |
| July 31, 2022 | -5.943M |
| April 30, 2022 | -6.028M |
| January 31, 2022 | -4.963M |
| October 31, 2021 | -4.937M |
| July 31, 2021 | -5.307M |
| April 30, 2021 | -5.117M |
| January 31, 2021 | -5.432M |
| October 31, 2020 | -6.176M |
| July 31, 2020 | -6.099M |
| April 30, 2020 | -5.448M |
| Date | Value |
|---|---|
| January 31, 2020 | -5.326M |
| October 31, 2019 | -4.741M |
| July 31, 2019 | -4.425M |
| April 30, 2019 | -4.955M |
| January 31, 2019 | -4.263M |
| October 31, 2018 | -4.273M |
| July 31, 2018 | -3.992M |
| April 30, 2018 | -4.073M |
| January 31, 2018 | -4.407M |
| October 31, 2017 | -3.797M |
| July 31, 2017 | -3.740M |
| April 30, 2017 | -3.304M |
| January 31, 2017 | -3.579M |
| October 31, 2016 | -3.382M |
| July 31, 2016 | -3.501M |
| April 30, 2016 | -3.394M |
| January 31, 2016 | -3.822M |
| October 31, 2015 | 1.363M |
| July 31, 2015 | 1.803M |
| April 30, 2015 | 2.174M |
| January 31, 2015 | 3.446M |
| October 31, 2014 | -2.379M |
| July 31, 2014 | -2.562M |
| April 30, 2014 | -3.064M |
| January 31, 2014 | -3.469M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -59.06M |
| Oncolytics Biotech, Inc. | -26.52M |
| Sangamo Therapeutics, Inc. | -90.34M |
| Sarepta Therapeutics, Inc. | 93.95M |
| Vicapsys Life Sciences, Inc. | -0.1292M |